Follow
  • Grey Instagram Icon
  • Grey Facebook Icon
  • Grey Twitter Icon
CONTACT

Texas A&M University

withpurposecs@gmail.com

We are the Texas A&M chapter of With Purpose, a nonprofit that raises money and awareness for childhood cancer research.

ABOUT

© 2017 by WPCS. Proudly created with Wix.com

RACE For Children Act

April 20, 2017

 

In March 2015, in the middle of my public speaking class’s campaign for With Purpose, the FDA approved the drug Unituxin to treat high-risk neuroblastoma. This made it the third of all drugs designed specifically for childhood cancer to be approved in the 21st century, joining Clolar (2004) and Erwinaze (2011), both used to treat acute lymphoblastic leukemia. The approval of Unituxin was in large part spurred by the Creating Hope Act of 2011, which created incentives for pediatric drug development in the form of priority review vouchers. During the semester, I gave a motivational speech encouraging my classmates to ask their members of Congress to reauthorize this act. Unituxin’s approval during our campaign felt like a meaningful coincidence, affirming that it was the right time to get involved and the right time to support legislation.

 

Now is another opportune time to support legislation. The Creating Hope Act was pioneered by Kids V. Cancer, one of the non-profits that With Purpose donates to, and they are now focusing their efforts on the RACE for Children Act. RACE updates the Pediatric Cancer Research Equity Act (PREA) of 2003, which required pharmaceutical companies to test their adult drugs in children if their cancer was in the same organ. PREA was a great idea, but pediatric cancers don’t often originate in the same parts of the body as adult cancers, so not a single PREA study has been conducted for pediatric cancer. However, as researchers now develop drugs based on molecular targets, they have recognized that adult and childhood cancers can share the same targets. For instance, an ALK inhibitor that treats adults with lung cancer also treats kids with neuroblastoma. RACE modernizes PREA to reflect our current scientific understanding of cancer, providing the FDA with the authority to require any new cancer drug to be studied in pediatric cancers for which the molecular target of the cancer drug is relevant. RACE also provides that cancer drugs with orphan designations would no longer be exempt from PREA requirements.

 

RACE was introduced to Congress on February 27th. If it is not passed this summer, we will have to wait 5 years to reintroduce it. During that time, an estimated 78,900 kids will be diagnosed with cancer in the U.S. alone. Click here to fill out a form letter that automatically sends to your representative and senators. The time to act is now.

 

Megan Nicholson

WPCS Vice President & Event Planning Team Leader 2015-2017

Share on Facebook
Share on Twitter
Please reload

Featured Posts

A Calling to Serve

October 20, 2018

1/4
Please reload

Recent Posts

October 20, 2018

August 20, 2018

Please reload

Follow Us
  • Grey Instagram Icon
  • Grey Facebook Icon
  • Grey Twitter Icon
Search By Tags